Cargando…
Growth Differentiation Factor 15 and NT‐proBNP as Blood‐Based Markers of Vascular Brain Injury and Dementia
BACKGROUND: GDF15 (growth differentiation factor 15) and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) may offer promise as biomarkers for cognitive outcomes, including dementia. We determined the association of these biomarkers with cognitive outcomes in a community‐based cohort. METHODS AN...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792414/ https://www.ncbi.nlm.nih.gov/pubmed/32921207 http://dx.doi.org/10.1161/JAHA.119.014659 |
_version_ | 1783633800534687744 |
---|---|
author | McGrath, Emer R. Himali, Jayandra J. Levy, Daniel Conner, Sarah C. DeCarli, Charles Pase, Matthew P. Ninomiya, Toshiharu Ohara, Tomoyuki Courchesne, Paul Satizabal, Claudia L. Vasan, Ramachandran S. Beiser, Alexa S. Seshadri, Sudha |
author_facet | McGrath, Emer R. Himali, Jayandra J. Levy, Daniel Conner, Sarah C. DeCarli, Charles Pase, Matthew P. Ninomiya, Toshiharu Ohara, Tomoyuki Courchesne, Paul Satizabal, Claudia L. Vasan, Ramachandran S. Beiser, Alexa S. Seshadri, Sudha |
author_sort | McGrath, Emer R. |
collection | PubMed |
description | BACKGROUND: GDF15 (growth differentiation factor 15) and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) may offer promise as biomarkers for cognitive outcomes, including dementia. We determined the association of these biomarkers with cognitive outcomes in a community‐based cohort. METHODS AND RESULTS: Plasma GDF15 (n=1603) and NT‐proBNP levels (n=1590) (53% women; mean age, 68.7 years) were measured in dementia‐free Framingham Offspring cohort participants at examination 7 (1998–2001). Participants were followed up for incident dementia. Secondary outcomes included Alzheimer disease dementia, magnetic resonance imaging structural brain measures, and neurocognitive performance. During a median 11.8‐year follow‐up, 131 participants developed dementia. On multivariable Cox proportional‐hazards analysis, higher circulating GDF15 was associated with an increased risk of incident all‐cause and Alzheimer disease dementia (hazard ratio [HR] per SD increment in natural log‐transformed biomarker value, 1.54 [95% CI, 1.22–1.95] and 1.37 [95% CI, 1.03–1.81], respectively), whereas higher plasma NT‐proBNP was also associated with an increased risk of all‐cause dementia (HR, 1.32; 95% CI, 1.05–1.65). Elevated GDF15 was associated with lower total brain and hippocampal volumes, greater white matter hyperintensity volume, and poorer cognitive performance. Elevated NT‐proBNP was associated with greater white matter hyperintensity volume and poorer cognitive performance. Addition of both biomarkers to a conventional risk factor model improved dementia risk classification (net reclassification improvement index, 0.25; 95% CI, 0.05–0.45). CONCLUSIONS: Elevated plasma GDF15 and NT‐proBNP were associated with vascular brain injury on magnetic resonance imaging, poorer neurocognitive performance, and increased risk of incident dementia in individuals aged >60 years. Both biomarkers improved dementia risk classification beyond that of traditional clinical risk factors, indicating their potential value in predicting incident dementia. |
format | Online Article Text |
id | pubmed-7792414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77924142021-01-15 Growth Differentiation Factor 15 and NT‐proBNP as Blood‐Based Markers of Vascular Brain Injury and Dementia McGrath, Emer R. Himali, Jayandra J. Levy, Daniel Conner, Sarah C. DeCarli, Charles Pase, Matthew P. Ninomiya, Toshiharu Ohara, Tomoyuki Courchesne, Paul Satizabal, Claudia L. Vasan, Ramachandran S. Beiser, Alexa S. Seshadri, Sudha J Am Heart Assoc Original Research BACKGROUND: GDF15 (growth differentiation factor 15) and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) may offer promise as biomarkers for cognitive outcomes, including dementia. We determined the association of these biomarkers with cognitive outcomes in a community‐based cohort. METHODS AND RESULTS: Plasma GDF15 (n=1603) and NT‐proBNP levels (n=1590) (53% women; mean age, 68.7 years) were measured in dementia‐free Framingham Offspring cohort participants at examination 7 (1998–2001). Participants were followed up for incident dementia. Secondary outcomes included Alzheimer disease dementia, magnetic resonance imaging structural brain measures, and neurocognitive performance. During a median 11.8‐year follow‐up, 131 participants developed dementia. On multivariable Cox proportional‐hazards analysis, higher circulating GDF15 was associated with an increased risk of incident all‐cause and Alzheimer disease dementia (hazard ratio [HR] per SD increment in natural log‐transformed biomarker value, 1.54 [95% CI, 1.22–1.95] and 1.37 [95% CI, 1.03–1.81], respectively), whereas higher plasma NT‐proBNP was also associated with an increased risk of all‐cause dementia (HR, 1.32; 95% CI, 1.05–1.65). Elevated GDF15 was associated with lower total brain and hippocampal volumes, greater white matter hyperintensity volume, and poorer cognitive performance. Elevated NT‐proBNP was associated with greater white matter hyperintensity volume and poorer cognitive performance. Addition of both biomarkers to a conventional risk factor model improved dementia risk classification (net reclassification improvement index, 0.25; 95% CI, 0.05–0.45). CONCLUSIONS: Elevated plasma GDF15 and NT‐proBNP were associated with vascular brain injury on magnetic resonance imaging, poorer neurocognitive performance, and increased risk of incident dementia in individuals aged >60 years. Both biomarkers improved dementia risk classification beyond that of traditional clinical risk factors, indicating their potential value in predicting incident dementia. John Wiley and Sons Inc. 2020-09-14 /pmc/articles/PMC7792414/ /pubmed/32921207 http://dx.doi.org/10.1161/JAHA.119.014659 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research McGrath, Emer R. Himali, Jayandra J. Levy, Daniel Conner, Sarah C. DeCarli, Charles Pase, Matthew P. Ninomiya, Toshiharu Ohara, Tomoyuki Courchesne, Paul Satizabal, Claudia L. Vasan, Ramachandran S. Beiser, Alexa S. Seshadri, Sudha Growth Differentiation Factor 15 and NT‐proBNP as Blood‐Based Markers of Vascular Brain Injury and Dementia |
title | Growth Differentiation Factor 15 and NT‐proBNP as Blood‐Based Markers of Vascular Brain Injury and Dementia |
title_full | Growth Differentiation Factor 15 and NT‐proBNP as Blood‐Based Markers of Vascular Brain Injury and Dementia |
title_fullStr | Growth Differentiation Factor 15 and NT‐proBNP as Blood‐Based Markers of Vascular Brain Injury and Dementia |
title_full_unstemmed | Growth Differentiation Factor 15 and NT‐proBNP as Blood‐Based Markers of Vascular Brain Injury and Dementia |
title_short | Growth Differentiation Factor 15 and NT‐proBNP as Blood‐Based Markers of Vascular Brain Injury and Dementia |
title_sort | growth differentiation factor 15 and nt‐probnp as blood‐based markers of vascular brain injury and dementia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792414/ https://www.ncbi.nlm.nih.gov/pubmed/32921207 http://dx.doi.org/10.1161/JAHA.119.014659 |
work_keys_str_mv | AT mcgrathemerr growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT himalijayandraj growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT levydaniel growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT connersarahc growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT decarlicharles growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT pasematthewp growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT ninomiyatoshiharu growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT oharatomoyuki growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT courchesnepaul growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT satizabalclaudial growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT vasanramachandrans growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT beiseralexas growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia AT seshadrisudha growthdifferentiationfactor15andntprobnpasbloodbasedmarkersofvascularbraininjuryanddementia |